What is the share price of Pharmaids Pharmaceuticals Ltd (PHARMAID) today?
The share price of PHARMAID as on 21st March 2025 is ₹69.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Pharmaids Pharmaceuticals Ltd (PHARMAID) share?
The past returns of Pharmaids Pharmaceuticals Ltd (PHARMAID) share are- Past 1 week: -4.93%
- Past 1 month: 14.74%
- Past 3 months: 14.34%
- Past 6 months: 69.88%
- Past 1 year: 28.50%
- Past 3 years: 383.58%
- Past 5 years: 1335.32%
What are the peers or stocks similar to Pharmaids Pharmaceuticals Ltd (PHARMAID)?
The peers or stocks similar to Pharmaids Pharmaceuticals Ltd (PHARMAID) include:What is the market cap of Pharmaids Pharmaceuticals Ltd (PHARMAID) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Pharmaids Pharmaceuticals Ltd (PHARMAID) is ₹237.92 Cr as of 21st March 2025.What is the 52 week high and low of Pharmaids Pharmaceuticals Ltd (PHARMAID) share?
The 52-week high of Pharmaids Pharmaceuticals Ltd (PHARMAID) is ₹87.46 and the 52-week low is ₹31.90.What is the PE and PB ratio of Pharmaids Pharmaceuticals Ltd (PHARMAID) stock?
The P/E (price-to-earnings) ratio of Pharmaids Pharmaceuticals Ltd (PHARMAID) is -29.89. The P/B (price-to-book) ratio is 3.37.Which sector does Pharmaids Pharmaceuticals Ltd (PHARMAID) belong to?
Pharmaids Pharmaceuticals Ltd (PHARMAID) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Pharmaids Pharmaceuticals Ltd (PHARMAID) shares?
You can directly buy Pharmaids Pharmaceuticals Ltd (PHARMAID) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Pharmaids Pharmaceuticals Ltd
PHARMAID Share Price
69.603.17% (+2.14)
PHARMAID Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
PHARMAID Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -19.25 | 3.37 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.25 | 6.29 | 0.54% |
PHARMAID Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PHARMAID Company Profile
Pharmaids Pharmaceuticals is engaged in the manufacturing of ayurvedic medicines and trading of allopathic medicines.
PHARMAID Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
43.85
1Y Return
12.97%
Buy Reco %
88.24
CIPLA
PE Ratio
29.63
1Y Return
6.68%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
66.01
1Y Return
28.26%
Buy Reco %
68.00
DRREDDY
PE Ratio
17.73
1Y Return
2.74%
Buy Reco %
45.16
LUPIN
PE Ratio
49.74
1Y Return
33.45%
Buy Reco %
63.64
PHARMAID Forecasts
Price
Revenue
Earnings
PHARMAID Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timePHARMAID Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timePHARMAID Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timePHARMAID
Income
Balance Sheet
Cash Flow
Annual Normal View
PHARMAID Income Statement
Annual Normal View
| Financial Year | FY 2022 | FY 2023 | FY 2024 | TTM | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.96 | 0.00 | 15.99 | 20.58 | ||||
Raw Materials | 4.09 | 0.00 | 10.31 | 35.03 | ||||
| Power & Fuel Cost | 0.00 | 0.00 | 1.04 | |||||
| Employee Cost | 0.04 | 1.13 | 9.20 | |||||
| Selling & Administrative Expenses | 0.19 | 0.76 | 3.44 | |||||
| Operating & Other expenses | -0.52 | 8.00 | 4.32 | |||||
EBITDA | 0.16 | -9.89 | -12.32 | -14.45 | ||||
| Depreciation/Amortization | 0.01 | 0.02 | 1.72 | 2.45 | ||||
| PBIT | 0.15 | -9.91 | -14.04 | -16.90 | ||||
| Interest & Other Items | 0.00 | 0.00 | 1.58 | 1.84 | ||||
| PBT | 0.15 | -9.91 | -15.62 | -18.74 | ||||
| Taxes & Other Items | 0.00 | -2.35 | -7.66 | -6.38 | ||||
| Net Income | 0.15 | -7.56 | -7.96 | -12.36 | ||||
| EPS | 0.07 | -3.52 | -2.81 | -3.50 | ||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 |
PHARMAID Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPHARMAID Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Pharmaids Pharmaceuticals Ltd | -29.89 | 3.37 | — |
| Sun Pharmaceutical Industries Ltd | 43.85 | 6.26 | 0.77% |
| Cipla Ltd | 29.63 | 4.56 | 0.86% |
| Torrent Pharmaceuticals Ltd | 66.01 | 15.95 | 0.87% |
PHARMAID Stock Price Comparison
Compare PHARMAID with any stock or ETFCompare PHARMAID with any stock or ETF
PHARMAID
PHARMAID Shareholdings
PHARMAID Promoter Holdings Trend
PHARMAID Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PHARMAID Shareholding Pattern
PHARMAID Shareholding History
Mutual Funds
smallcases containing PHARMAID stock
Looks like this stock is not in any smallcase yet.
PHARMAID Events
PHARMAID Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PHARMAID has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PHARMAID Dividends
Hmm, looks like data is unavailable here. Please come back after some timePHARMAID Stock News & Opinions
Articles & Videos
Earnings
Pharmaids Pharmaceuticals reports consolidated net loss of Rs 1.93 crore in the December 2024 quarter
Net Loss of Pharmaids Pharmaceuticals reported to Rs 1.93 crore in the quarter ended December 2024 as against net loss of Rs 1.15 crore during the previous quarter ended December 2023. Sales rose 23450.00% to Rs 4.71 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales4.710.02 23450 OPM %-61.36-12150.00 - PBDT-3.36-1.69 -99 PBT-4.00-1.73 -131 NP-1.93-1.15 -68 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Pharmaids Pharmaceuticals reports standalone net loss of Rs 1.59 crore in the December 2024 quarter
Net Loss of Pharmaids Pharmaceuticals reported to Rs 1.59 crore in the quarter ended December 2024 as against net loss of Rs 1.15 crore during the previous quarter ended December 2023. Sales rose 5950.00% to Rs 1.21 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1.210.02 5950 OPM %-142.15-12150.00 - PBDT-1.79-1.69 -6 PBT-1.84-1.73 -6 NP-1.59-1.15 -38 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Pharmaids Pharmaceuticals to table results
Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Pharmaids Pharmaceuticals reports consolidated net loss of Rs 2.22 crore in the September 2024 quarter
Net Loss of Pharmaids Pharmaceuticals reported to Rs 2.22 crore in the quarter ended September 2024 as against net loss of Rs 0.50 crore during the previous quarter ended September 2023. Sales reported to Rs 5.24 crore in the quarter ended September 2024. There were no Sales reported during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5.240 0 OPM %-48.660 - PBDT-2.88-1.28 -125 PBT-3.49-1.29 -171 NP-2.22-0.50 -344 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Pharmaids Pharmaceuticals to announce Quarterly Result
Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Pharmaids Pharmaceuticals AGM scheduled
Pharmaids Pharmaceuticals announced that the 35th Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Pharmaids Pharmaceuticals to convene board meeting
Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 August 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Pharmaids Pharmaceuticals reports consolidated net loss of Rs 2.68 crore in the June 2024 quarter
Net Loss of Pharmaids Pharmaceuticals reported to Rs 2.68 crore in the quarter ended June 2024 as against net loss of Rs 1.30 crore during the previous quarter ended June 2023. Sales reported to Rs 4.67 crore in the quarter ended June 2024. There were no Sales reported during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.670 0 OPM %-72.810 - PBDT-3.66-1.20 -205 PBT-4.22-1.21 -249 NP-2.68-1.30 -106 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Pharmaids Pharmaceuticals schedules board meeting
Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant